Hemogenyx Pharmaceuticals plc announced that a patent application entitled Method of Eliminating Hematopoietic Stem Cells/Hematopoietic Progenitors (HSC/HP) In A Patient Using Bi-Specific Antibodies has been allowed to be issued as a patent by the United States Patent and Trademark Office.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.54 GBX | +0.98% | -1.60% | -33.04% |
04-25 | EARNINGS: LSL starts 2024 "strongly"; Focusrite maintains payout | AN |
04-25 | Hemogenyx Pharmaceuticals Plc Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-33.04% | 25.86M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- SILF Stock
- News Hemogenyx Pharmaceuticals Plc
- Hemogenyx Pharmaceuticals plc Announces Approval and Issuance of U.S. Conditioning Patent